Open Access Policy Deposits
Parent: Department of Molecular and Medical Pharmacology
eScholarship stats: Breakdown by Item for May through August, 2026
| Item | Title | Total requests | Download | View-only | %Dnld |
|---|---|---|---|---|---|
| 3rh986fd | Macrophage COX2 Mediates Efferocytosis, Resolution Reprogramming, and Intestinal Epithelial Repair | 1,053 | 81 | 972 | 7.7% |
| 0290023m | B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer | 639 | 564 | 75 | 88.3% |
| 4450x915 | Targeting PEA3 transcription factors to mitigate small cell lung cancer progression | 637 | 541 | 96 | 84.9% |
| 4sk065dz | Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial | 635 | 534 | 101 | 84.1% |
| 19k5q59f | The pentose phosphate pathway in health and disease | 624 | 242 | 382 | 38.8% |
| 4xj2w70k | Chapter Five Advances in PET Detection of the Antitumor T Cell Response | 573 | 509 | 64 | 88.8% |
| 54c114pc | Multivalent N‑Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing | 538 | 182 | 356 | 33.8% |
| 47h17394 | PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 | 472 | 112 | 360 | 23.7% |
| 837669fc | Individual islet respirometry reveals functional diversity within the islet population of mice and human donors | 432 | 25 | 407 | 5.8% |
| 7jm3422h | PD-1 blockade induces responses by inhibiting adaptive immune resistance | 424 | 289 | 135 | 68.2% |
| 9623t7mm | Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence | 422 | 172 | 250 | 40.8% |
| 1zv2z6bg | RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults | 409 | 232 | 177 | 56.7% |
| 9292w8n6 | Multiple early factors anticipate post-acute COVID-19 sequelae | 408 | 137 | 271 | 33.6% |
| 61s0k68s | Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | 397 | 230 | 167 | 57.9% |
| 87s8b0ff | Isolation of Mitochondria from Mouse Tissues for Functional Analysis | 390 | 137 | 253 | 35.1% |
| 5gr4m7rp | Mammary duct luminal epithelium controls adipocyte thermogenic programme | 368 | 299 | 69 | 81.3% |
| 5nv9f110 | Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression | 358 | 206 | 152 | 57.5% |
| 0cj1q8m0 | Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations | 357 | 280 | 77 | 78.4% |
| 69s4b6hb | Osteopontin as a Biomarker in Chronic Kidney Disease | 355 | 108 | 247 | 30.4% |
| 5xq2c221 | Metabolic programs of T cell tissue residency empower tumour immunity | 341 | 192 | 149 | 56.3% |
| 2v0702dq | ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma | 332 | 269 | 63 | 81.0% |
| 9br8v18z | Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients | 324 | 102 | 222 | 31.5% |
| 7rq9k34t | Vaccine adjuvants: current status, research and development, licensing, and future opportunities | 322 | 150 | 172 | 46.6% |
| 0f01h1g6 | TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination | 318 | 236 | 82 | 74.2% |
| 1n83k1hm | The “cancer immunogram” | 314 | 49 | 265 | 15.6% |
| 87x612c2 | Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma | 314 | 219 | 95 | 69.7% |
| 5mp7824g | Immunoresponsive Gene 1 and Itaconate Inhibit Succinate Dehydrogenase to Modulate Intracellular Succinate Levels* | 311 | 106 | 205 | 34.1% |
| 0zv4p7dc | Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions | 309 | 204 | 105 | 66.0% |
| 10s8335f | Gynecologic tumor board: a radiologist’s guide to vulvar and vaginal malignancies | 305 | 182 | 123 | 59.7% |
| 7w98t225 | Etomoxir Inhibits Macrophage Polarization by Disrupting CoA Homeostasis | 304 | 68 | 236 | 22.4% |
| 0bh4n1vq | Targeted agents and immunotherapies: optimizing outcomes in melanoma | 301 | 195 | 106 | 64.8% |
| 2r15x44h | Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) | 298 | 78 | 220 | 26.2% |
| 4zw2v599 | CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer | 297 | 200 | 97 | 67.3% |
| 1387q04m | Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | 293 | 65 | 228 | 22.2% |
| 6t49338z | The whole-genome landscape of medulloblastoma subtypes | 291 | 180 | 111 | 61.9% |
| 7k76k99h | Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival | 291 | 59 | 232 | 20.3% |
| 46k649vw | Mitochondria Bound to Lipid Droplets Have Unique Bioenergetics, Composition, and Dynamics that Support Lipid Droplet Expansion | 288 | 50 | 238 | 17.4% |
| 0g72g9bm | Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. | 281 | 69 | 212 | 24.6% |
| 6v3011pd | Cancer immunotherapy using checkpoint blockade | 279 | 59 | 220 | 21.1% |
| 4jr8j2cx | UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas | 276 | 154 | 122 | 55.8% |
| 0cj235rr | Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma | 271 | 165 | 106 | 60.9% |
| 5pj4p43b | Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method | 271 | 196 | 75 | 72.3% |
| 4z6394j3 | Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing | 270 | 43 | 227 | 15.9% |
| 8094s6nw | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction | 270 | 80 | 190 | 29.6% |
| 5f52f92h | Antitumor Immune Responses in B2M-Deficient Cancers | 267 | 146 | 121 | 54.7% |
| 342329sk | Context-dependent regulation of ferroptosis sensitivity | 264 | 130 | 134 | 49.2% |
| 2g96s8v7 | Non-viral precision T cell receptor replacement for personalized cell therapy | 260 | 203 | 57 | 78.1% |
| 5673156t | The Ca2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum | 256 | 56 | 200 | 21.9% |
| 0t4090cx | Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer | 255 | 112 | 143 | 43.9% |
| 0fq0574t | Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial | 252 | 126 | 126 | 50.0% |
Note: Due to the evolving nature of web traffic, the data presented here should be considered approximate and subject to revision. Learn more.